CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 31 pages
Chikungunya epidemiology in U.S. territories and states with risk of transmissionNational Center for Emerging and Zoonotic Infectious Diseases Susan Hills MBBS MTH CDC Lead , Chikungunya Vaccines Work Group Arboviral Diseases Branch Division of Vector- Borne Diseases Fort Collins, Colorado ACIP Meeting, June 26, 2024 •Mosquito -borne disease •Key vectors are Aedes aegypti and Aedes albopictus mosquitoesChikungunya •Typically tropical and subtropical regions •Periodically causes large…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 32 pages
1 Cost -effectiveness of live attenuated chikungunya vaccine among adults living in US territories Kelly Kilburn, PhD, Martin I. Meltzer, PhD, Seonghye Jeon, PhD, Susan L. Hills, MBBS, MTH, Bishwa B. Adhikari, PhD, Nicole P. Lindsey, MS, J. Erin Staples, MD, PhD June 27th, 2024 National Center for Emerging Zoonotic and Infectious DiseasesNational Center for Emerging Zoonotic and Infectious Diseases 2•Authors have no known conflict of interests •The findings and conclusions in this…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 4 pages
Next steps for the Chikungunya Vaccines Work GroupNational Center for Emerging and Zoonotic Infectious Diseases Susan Hills MBBS MTH CDC Lead , Chikungunya Vaccines Work Group Arboviral Diseases Branch Division of Vector -Borne Diseases Fort Collins, Colorado ACIP Meeting, June 26, 2024 •Work Group gathering data and will discuss additional important considerations including: -Acceptability and value of vaccine to providers and relevant populations -Feasibility of administration Consideration…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 4 pages
June 26 – ACIP Meeting Dengvaxia®Next Steps Nicholas Bergren PhD, MBA Director, Scientific and Medical Affairs 1 Internal 22021 ACIP Recommendation for Dengvaxia®: ACIP recommends vaccination with the Dengvaxia® vaccine for children aged 9–16 years having evidence of a previous dengue infection and living in areas where dengue is endemic . Dengvaxia® is recommended as a 3-dose vaccination series, administered 6 months apart (at month 0, 6, and 12)for the selected …
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 21 pages
Update on Dengue Vaccines Joshua Wong, MD Medical Officer | NCEZID/DVBD/Dengue Branch Meeting of the Advisory Committee on Immunization Practices June 26, 2024National Center for Emerging and Zoonotic Infections 1 Dengue Epidemiology Globally Countries reporting locally acquired dengue cases, March 2023 –April 2024 Image from: https://www.ecdc.europa.eu/en/publications -data/countriesterritories -reporting -dengue -cases -march -2023 -and-april -2024 . Accessed 6/1/2024 Dengue cases in the…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 10 pages
ACIP COVID -19 Vaccines Work Group Dr. Matthew F. Daley, Work Group Chair June 27, 2024National Center for Immunization and Respiratory Diseases •ACIP met September 12, 2023 and recommended 2023 -2024 COVID -19 vaccines as authorized under EUA or approved by BLA in persons aged ≥6 months -Moderna COVID -19 vaccine in persons ≥6 months -Pfizer -BioNTech COVID -19 vaccine in persons ≥6 months -Novavax COVID -19 vaccine in persons ≥ 12 years* •Everyone aged 5 years and older should get 1…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 24 pages
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Photographs and images included in this presentation are licensed solely for CDC/NCIRD online and presentation use. No rights are implied or extended for use in printing or any use by other CDC CIOs or any external audiences. COVID -19–Associated Hospitalizations among Children and Adults — COVID -NET ACIP Meeting Fiona P . Havers, MD, MHS RESP -NET Hospitalization Surveillance Team…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 30 pages
Effectiveness of COVID -19 (2023-2024 Formula) vaccines Ruth Link-Gelles, PhD, MPH CDR, US Public Health Service Vaccine Effectiveness Program Lead Coronavirus and Other Respiratory Viruses Division Centers for Disease Control and Prevention June 27, 2024National Center for Immunization and Respiratory Diseases •Vaccine effectiveness (VE) methods refresher •Context for interpretation of COVID -19 VE •COVID -19 VE in adults, by outcome and variant: -Symptomatic SARS -CoV-2 -COVID…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 41 pages
COVID -19 vaccine safety surveillance for the 2023 -2024 season Jonathan Duffy, MD, MPH Immunization Safety Office June 27, 2024National Center for Emerging and Zoonotic Infectious Diseases •Vaccine Adverse Event Reporting System (VAERS) •V-s afe •Vaccine Safety Datalink (VSD)CDC surveillance systems monitoring COVID -19 vaccine safety 2 •The Vaccine Safety Datalink (VSD) identified two statistical signals for mRNA COVID- 1 9 vaccines during the 2023 -2024 season -Guillain -B arré…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 38 pages
Economic analysis of COVID -19 vaccination University of Michigan COVID -19 Vaccination Modeling Team ACIP Meeting June 24, 2024 1 Study team University of Michigan • Lisa A. Prosser, PhD, Principal Investigator • David W. Hutton, PhD, Co -Investigator • Acham Gebremariam, MS, Programmer/Analyst • Angela Rose, MS, MPH, Project Manager • Christina Nyamuswa, Research Assistant Wake Forest University • Cara Janusz, PhD Centers for Disease Control and Prevention •…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 131 pages
National Center for Immunization and Respiratory Diseases Evidence to Recommendations Framework: 2024 -2025 COVID -19 Vaccines in Persons ≥6 Months of Age Lakshmi Panagiotakopoulos, MD, MPH ACIP Meeting June 27, 2024 Evidence to Recommendations (EtR) Framework Policy Question • Should 2024 – 2025 COVID -19 vaccines be recommended for use in persons ≥6 months of age? • Products and ages under review for authorization or approval by FDA include: -Moderna COVID -19 vaccine…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 28 pages
COVID -19 Vaccine Implementation Shannon Stokley, DrPH Deputy Director for Science Implementation Immunization Services Division National Center for Immunizations and Respiratory Diseases (NCIRD) June 2024National Center for Immunization and Respiratory Diseases 2023 -2024 COVID -19 Vaccination Coverage Percentage of Children Ages 6 Months –17 Years Who Are Up to Date with the 2023-2024 COVID-19 Vaccine, NIS-CCM and NIS-FLU As of May 11, 2024, vaccination coverage among children was…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 6 pages
National Center for Immunization & Respiratory Diseases Influenza Work Group— Introduction Dr. Jamie Loehr (Work Group Chair) Advisory Committee on Immunization Practices June 27, 2024 Influenza Work Group ACIP Members •Jamie Loehr (Chair) •Denise Jamieson •Camille Kotton •Robert Schechter •Keipp Talbot Ex Officio •Timothy Brennan (FDA) •Uzo Chukwuma (IHS) •Michael Ison (NIH) •Cynthia Nolletti (FDA) •Jo Resnick (FDA) •Chris Roberts (NIH)Liaison Representatives and Consultants •Robert Atmar…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 16 pages
Highly Pathogenic Avian Influenza A(H5N1) Vivien G. Dugan, PhD Director, Influenza Division National Center for Immunization and Respiratory Diseases Centers for Disease Control and Prevention June 27, 2024 •HPAI A(H5N1) detected in birds in 1996 A( H5N1) is n ot a new threat •Sporadic HPAI A(H5N1) virus infections of mammals have been reported since 2003 -2004 •A(H5N1) clade 2.3.4.4b viruses emerged in wild b irds in 2020 •29 human cases of HPAI A(H5N1) have been d etected globally…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 50 pages
U.S. Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Photographs and images included in this presentation are licensed solely for CDC/NCIRD online and presentation use. No rights are implied or extended for use in printing or any use by other CDC CIOs or any external audiences. Influenza Updates, Work Group Considerations, and Proposed Recommendations for the 2024 -25 Influenza Season Lisa Grohskopf, Jill Ferdinands, and Lenee Blanton…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 14 pages
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Photographs and images included in this presentation are licensed solely for CDC/NCIRD online and presentation use. No rights are implied or extended for use in printing or any use by other CDC CIOs or any external audiences. Pneumococcal Vaccines June 2024, ACIP Meeting June 27, 2024 Pneumococcal Vaccine Work Group Chair James Loehr, MD, FAAFP ACIP Members ▪Jamie Loehr (Chair) ▪Sarah Long…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 45 pages
1Economic Assessment of PCV21 in U.S. Adults Charles Stoecker Tulane University School of Public Health and Tropical Medicine ACIP June 27, 2024 2Conflicts of Interest ❑Dr. Stoecker has no conflicts of interest to declare. 3Acronyms ❑ PCV: pneumococcal conjugate vaccine ❑ PCV20: 20 valent PCV ❑ PCV21: 21 valent PCV ❑ VE: vaccine effectiveness ❑ VT: vaccine type ❑ ST: serotype ❑ NBP: non -bacteremic pneumonia ❑ IPD: invasive pneumococcal disease ❑ IPT: inpatient ❑ OPT: outpatient ❑ QALY:…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 21 pages
Summary of three economic analyses on the use of 21-valent pneumococcal conjugate vaccine (PCV21) among adults in the United States Andrew J. Leidner, PhD Applied Research, Implementation Science and Evaluation (ARISE) Branch Immunization Services Division (ISD) NCIRD ACIP Meeting June 27, 2024NCIRD/ISD/ARISE The findings and conclusions in this report are those of the author and do not necessarily represent the views of the Centers for Disease Control and Prevention.1 •This presentation…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 55 pages
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Summary of Work Group Interpretations of EtR and Policy Option on PCV21 Use in Adults June 2024, ACIP Meeting June 27, 2024 Miwako Kobayashi, MD, MPH, FACP , FIDSA Photographs and images included in this presentation are licensed solely for CDC/NCIRD online and presentation use. No rights are implied or extended for use in printing or any use by other CDC CIOs or any external…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 6 pages
Introduction to Session: Meningococcal Vaccines Jamie Loehr, MD Chair, ACIP Meningococcal/Hib Vaccines Work Group June 28, 2024National Center for Immunization & Respiratory Diseases 1 ACIP Meningococcal/Hib Vaccines Work Group ▪ ACIP Members on the WG •Jamie Loehr (Chair) •Wilbur Chen ▪ Ex Officio WG Members •Margaret Bash (FDA) •Matthew Clark (IHS) •Xin-Xing Gu (NIH) ▪ WG Liaisons and Consultants •Amra Resic (AAFP) •Mary Healy (AAP) •Barb Fluty (ACHA) •Karyn Lyons (AIM) •Paul Cieslak…